2023 World Conference on Lung Cancer (Posters)-EP13.06. Real-World Outcomes in Patients with 3rd-Line Extensive Stage Small Cell Lung Cancer

EP13.06. Real-World Outcomes in Patients with 3rd-Line Extensive Stage Small Cell Lung Cancer - PDF(Slides)

Pdf Summary

A retrospective study was conducted to assess the real-world clinical outcomes of patients with extensive stage small cell lung cancer (SCLC) who received third-line (3L) treatment. The study included a total of 113 patients, most of whom were white and non-Hispanic. The patients were categorized into platinum-resistant and platinum-sensitive groups based on their response to first-line (1L) platinum-based chemotherapy.<br /><br />The study found that the response rates, duration of response (DOR), duration of benefit response (DOBR), overall survival (OS), and progression-free survival (PFS) were generally low among the patients. The median DOR was 2.8 months, while the median OS was 5.8 months. The majority of patients (67%) had no response to treatment at the 3L stage.<br /><br />The study also compared the outcomes between platinum-resistant and platinum-sensitive patients. It was found that platinum-resistant patients had shorter DOR, DOBR, OS, and PFS in both 1L and 2L treatment stages.<br /><br />No significant differences were observed in the response rates and time to event outcomes based on Eastern Cooperative Oncology Group (ECOG) status. However, it is worth noting that the study found limited clinical benefits with current therapies in this population.<br /><br />Overall, the study highlights the need for novel therapies to improve the response and disease progression in patients with extensive stage SCLC. More research is warranted in this area.

Asset Subtitle

Jair Bar

Meta Tag

Speaker Jair Bar

Topic SCLC & Neuroendocrine Tumors: Preclinical

Keywords

retrospective study

clinical outcomes

extensive stage small cell lung cancer

third-line treatment

platinum-resistant

platinum-sensitive

response rates

duration of response

overall survival

progression-free survival